I have a confession.
I like looking at FDA warning letters.
Not because I want companies to get in trouble. I do not. Most of these companies were probably moving fast, hiring normal marketers, using normal website language, and trying to make complicated medication access easier to understand.
But that is exactly the point.
The language that feels obvious to a growth team can read very differently to a regulator.
In February 2026, the FDA sent a wave of warning letters to compounded GLP-1 telehealth operators. The same patterns kept showing up: copy that made compounded products sound too close to FDA-approved brands, and product images or labels that made the telehealth company look like the compounder.
This page makes those patterns concrete.
It is not a list of villains. It is a teardown of the copy mistakes that are easy to miss when everyone in the category starts sounding the same.
If you want help finding this kind of risk before it shows up in a campaign, start with the Telehealth Growth Score or book a free strategy call.
Source note: The original build spec referenced nineteen companies. This v1 uses the six companies with clean source-backed FDA letters and usable Wayback evidence in the local research file. SkinnyRx has a usable FDA letter but the Wayback capture is a thin app shell, so that section is text-first.
Quick table
| Company | Pattern FDA flagged | Before evidence |
|---|---|---|
| Measured | Sameness | FDA quote and Wayback snapshot |
| SkinnyRx | Sourcing plus sameness claims | FDA quote only |
| Join Josie | Both | FDA quote and Wayback snapshot |
| Ivim | Sourcing | FDA description and Wayback snapshot |
| 24HrDoc | Both | FDA quote and Wayback snapshot |
| FitRx | Both | FDA quote and Wayback snapshot |
Measured (Better Health Labs)
FDA letter: Better Health Labs, Inc. dba Measured, 721454, February 20, 2026
Before
FDA-flagged copy:
“Measured offers compounded GLP-1 treatments made with the same active ingredients found in Wegovy®, Ozempic®, Zepbound®, and Mounjaro®.”
“Same active ingredient in Ozempic and Wegovy”
“Same active ingredient in Mounjaro and Zepbound”
Pattern: sameness
After
Measured offers access to clinician-reviewed weight care that may include compounded semaglutide or tirzepatide when appropriate. Compounded medications are not FDA-approved and are not the same as Ozempic, Wegovy, Mounjaro, or Zepbound. Treatment decisions should be made by a licensed clinician based on patient history, eligibility, and follow-up needs.
What changed: The rewrite stops using brand-name sameness as the trust shortcut and replaces it with clinical review, ingredient clarity, and the non-FDA-approved disclosure.
SkinnyRx (Lean Rx)
FDA letter: Lean Rx, Inc. dba SkinnyRx, 717989, February 20, 2026
Before
The Wayback capture for SkinnyRx resolves, but the captured page is a thin app shell. For this v1, the FDA letter is the source of the before copy.
FDA-flagged copy:
“from the same family as GLP-1 treatments like Mounjaro® and Zepbound®”
“Get access to the same active ingredient as name-brand GLP-1 medications”
“It contains the same active ingredient as FDA-approved medications”
Pattern: sourcing plus sameness claims
After
SkinnyRx connects eligible patients with licensed clinical review for weight management. When compounded GLP-1 medication is prescribed, the product is prepared by a separate compounding pharmacy and is not FDA-approved. It should not be described as the same as a branded GLP-1 medication.
What changed: The rewrite names the care model, separates the telehealth brand from the compounding pharmacy, and removes the “same active ingredient” hook.
Join Josie
FDA letter: Join Josie, 717986, February 20, 2026
Before
FDA-flagged copy:
“The same active ingredient found in the FDA-approved brand Wegovy®.”
“The same active ingredient found in the FDA-approved brand Zepbound®.”
Pattern: both
After
Join Josie helps eligible patients explore menopause and weight-care options with clinical oversight. If compounded semaglutide or tirzepatide is prescribed, it is not FDA-approved and should be presented as a compounded product from the dispensing pharmacy, not as a substitute for Wegovy or Zepbound.
What changed: The rewrite keeps the patient-facing promise but removes the brand comparison and clarifies that the compounded product should not appear to be made by the telehealth brand.
Ivim (Ivim Services LLC)
FDA letter: Ivim Services LLC dba Ivim, 721816, February 20, 2026
Before
The FDA letter did not list a separate sameness claim for Ivim in the same way it did for several other operators. The issue was sourcing. The FDA said the products displayed on the site identified “Ivim” on the pictured label, suggesting Ivim was the compounder when it was not.
Pattern: sourcing
After
Ivim can describe the clinical program, clinician oversight, and patient support. Product visuals should make the dispensing source clear. If a compounded medication is shown or discussed, the copy should state that the medication is compounded by a separate pharmacy and is not FDA-approved.
What changed: The rewrite separates the care brand from the product source and makes the compounding disclosure part of the visible trust layer.
24HrDoc
FDA letter: 24HrDoc, Inc. dba 24HrDoc, 717984, February 20, 2026
Before
The archived page resolves, but the frozen image endpoint does not reliably hotlink outside Wayback. For this v1, the FDA letter and archived page snapshot are the before evidence.
FDA-flagged copy:
“Same ingredients as: Ozempic and Wegovy”
“Same ingredients as: Mounjaro and Zepbound”
Pattern: both
After
24HrDoc offers online clinical evaluation for eligible patients seeking weight-care support. If a clinician prescribes compounded semaglutide or tirzepatide, the medication is compounded by a pharmacy, is not FDA-approved, and should not be marketed as the same as Ozempic, Wegovy, Mounjaro, or Zepbound.
What changed: The rewrite removes the side-by-side brand-name comparison and replaces it with care pathway, pharmacy source, and non-FDA-approved disclosure.
FitRx (FitRX, LLC)
FDA letter: FitRX, LLC dba FitRx, 717987, February 20, 2026
Before
FDA-flagged copy:
“semaglutide (active ingredient in Wegovy) or tirzepatide (active ingredient in Zepbound)”
“we can ship semaglutide, the main active ingredient in Wegovy and Ozempic, or Tirzepatide, the main active ingredient in Zepbound and Mounjaro”
Pattern: both
After
FitRx can say that licensed clinicians may prescribe compounded semaglutide or tirzepatide when clinically appropriate. The copy should also say the medication is compounded by a separate pharmacy, is not FDA-approved, and should not be presented as interchangeable with Wegovy, Ozempic, Zepbound, or Mounjaro.
What changed: The rewrite keeps the medication category clear but removes the branded-drug equivalence frame.
The rule underneath all six examples
The common mistake is not that these companies talked about GLP-1s.
The mistake is that the copy used branded-drug familiarity to create trust.
That is tempting because it works. Patients know Ozempic. They know Wegovy. They may not know what compounded semaglutide means.
But in a regulated category, the shortcut becomes the risk.
Clean GLP-1 copy usually needs five things:
- Say what the care model is.
- Say who evaluates the patient.
- Say when compounded medication may be considered.
- Say compounded products are not FDA-approved.
- Do not make the compounded product sound like the branded product wearing a cheaper label.
Rewrite your own copy with the same rule set
You are a regulatory-aware copywriter for a telehealth operator that sells compounded
GLP-1 medications. Rewrite the following ad copy so it follows the FDA patterns
surfaced in the February 2026 warning letters.
INPUT COPY:
{paste the original ad copy here}
COMPLIANCE RULES:
1. Never imply the compounded product is "the same as" or "equivalent to" any
FDA-approved drug, including Ozempic, Wegovy, Mounjaro, or Zepbound. You may name
the molecular ingredient, but only with an explicit disclosure that the compounded
version is not FDA-approved.
2. Disclose the upstream compounding pharmacy by name, or identify the legal pathway
if the pharmacy name cannot be used. The telehealth brand should not look like the
manufacturer or compounder by default.
3. Do not use branded drug trade dress, pen shape, color scheme, or logo-adjacent
visual language.
4. State that compounded products are not FDA-approved.
5. Qualify or remove efficacy and safety claims that are not specific to the actual
compounded product and care model.
OUTPUT FORMAT:
1. Rewrite the ad copy as one short paragraph in plain language.
2. Add one sentence naming which pattern the original triggered: sameness, sourcing, or both.
3. Add one sentence explaining which part of the rewrite addresses the issue.Final note
This is not legal advice. It is a practical marketing review using public FDA warning letters.
The lesson is simple: strong healthcare marketing is not just about sharper hooks.
It is about copy you can stand behind.
If you are about to launch, refresh, or scale a GLP-1 campaign, run the page through this filter before you spend more money on traffic. If the copy is too close to the warning-letter pattern, the ad is not ready.
Book a free strategy call or start with the Telehealth Growth Score.